.jetcityimage/iStock Editorial using Getty Images Morgan Stanley has selected Eli Lilly (NYSE: LLY) as its top biopharma choice for 2025 and also ranked another 9 titles in the area as obese. The assets bank said in a note that it remains to think “diabesity is actually set to come to be.